The extensive and positive preclinical results that have been obtained to date, many of which are now published in premier per-reviewed scientific journals, have been the products of several years of effort by the Company’s researchers as well as by a number of collaborating research teams at Dalhousie University, McMaster University, the National Research Council of Canada (NRC) labs, teaching hospitals in Halifax, Nova Scotia and CROs -- Jubilant Life Sciences, Syngene/Biocon, Biovectra and Foresight Regulatory Strategies.
Principal Advisors and Collaborators involved with core development of anti-infective DIBI:
Craig Woods
DVM
Midwest U USA
(CPI board of directors)
Veterinary infection expert
Paul Fidel
Ph.D.
Louisiana State U USA
Antibiotic resistant fungal vaginal infection expert
Ross Davidson
Ph.D.
Director bacteriology QEII Hospital Halifax
Clinical microbiology expert
Howard Xu
Ph.D.
Cal State U
Bacterial pneumonia expert
Matthias Bierenstiel
Ph.D.
Chair organic chemistry Cape Breton U Canada
Metal chemistry expert
Wangxue Chen
Ph.D.
HHTP National. Res. Council Canada
Bacterial pathogenesis expert
Lori Burrows
Ph.D.
DeGroote Infectious Dis. Res Inst Canada
Bacterial antibiotic resistance expert
Kendra Rumbaugh
Ph.D.
Texas Tech U USA
Pseudomonas burn/wound infection expert
Trialstat/ Jubilant Life Sciences Canada
CRO for DIBI toxicity studies
Other collaborator-led complementary platform aspects:
Christian Lehmann
MD
Dalhousie U
Inflammatory disease and bacterial sepsis expert
David Hoskin
Ph.D.
Dalhousie U
Breast cancer research chair, chemo resistant cancer expert